U.S., March 21 -- ClinicalTrials.gov registry received information related to the study (NCT07485647) titled 'Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing' on March 16.
Brief Summary: This phase II trial tests daratumumab given at a reduced frequency with lenalidomide for maintenance therapy for the cost effective treatment of patients with multiple myeloma post stem cell transplant. Darzalex Faspor (also known as Daratumumab-hyaluronidase) is a combination of two drugs used alone or with other drugs to treat adults with certain types of multiple myeloma or light chain amyloidosis. Daratumumab binds to a protein called CD38, which is found on some types of immune cells and cancer cells, including myeloma cells. D...